- Home
- GRAL vs QSI Comparison
GRAL vs QSI Comparison
Compare GRAL & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- QSI
- Stock Information
- Founded
- GRAL 2016
- QSI 2013
- Country
- GRAL United States
- QSI United States
- Employees
- GRAL N/A
- QSI N/A
- Industry
- GRAL
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- QSI Health Care
- Exchange
- GRAL NYSE
- QSI Nasdaq
- Market Cap
- GRAL 610.9M
- QSI 633.2M
- IPO Year
- GRAL N/A
- QSI N/A
- Fundamental
- Price
- GRAL $28.61
- QSI $2.30
- Analyst Decision
- GRAL Hold
- QSI Buy
- Analyst Count
- GRAL 2
- QSI 2
- Target Price
- GRAL $16.00
- QSI $3.25
- AVG Volume (30 Days)
- GRAL 893.1K
- QSI 59.7M
- Earning Date
- GRAL 02-15-2025
- QSI 02-27-2025
- Dividend Yield
- GRAL N/A
- QSI N/A
- EPS Growth
- GRAL N/A
- QSI N/A
- EPS
- GRAL N/A
- QSI N/A
- Revenue
- GRAL $117,669,000.00
- QSI $2,266,000.00
- Revenue This Year
- GRAL $32.48
- QSI $193.90
- Revenue Next Year
- GRAL $14.72
- QSI $173.18
- P/E Ratio
- GRAL N/A
- QSI N/A
- Revenue Growth
- GRAL 111.83
- QSI 232.26
- 52 Week Low
- GRAL $12.33
- QSI $0.61
- 52 Week High
- GRAL $29.79
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- QSI 49.43
- Support Level
- GRAL N/A
- QSI $2.26
- Resistance Level
- GRAL N/A
- QSI $2.58
- Average True Range (ATR)
- GRAL 0.00
- QSI 0.53
- MACD
- GRAL 0.00
- QSI -0.12
- Stochastic Oscillator
- GRAL 0.00
- QSI 11.48
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.